GoodRx Holdings Inc (GDRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
GoodRx Holdings, Inc. - Class A (GDRX)
Company Research
Source: Yahoo! Finance
Full Year Adjusted EBITDA (2024): $260.2 million, up 20% year-over-year Prescription Transactions Revenue (2024): $577.5 million, up 5% year-over-year Subscription Revenue (2024): $86.5 million, declined 8% year-over-year Pharma Manufacturer Solutions Revenue (2024): $107.2 million, up 26% year-over-year Net Income (2024): $16.4 million, compared to a net loss of $8.9 million in 2023 Adjusted Net Income (2024): $131.6 million, up from $114.6 million in 2023 Adjusted EBITDA Margin (2024): 32.8%, up 420 basis points year-over-year Net Cash from Operating Activities (2024): $183.9 million Ending Cash on Hand (2024): $448.3 million Outstanding Debt (2024): $500 million Total Liquidity (2024): Approximately $540 million 2025 Revenue Guidance: $810 million to $840 million 2025 Adjusted EBITDA Guidance: $270 million to $286 million Q1 2025 Revenue Guidance: $201 million to $205 million Q1 2025 Adjusted EBITDA Margin Guidance: Approximately 33% Warning! GuruFocu
Show less
Read more
Impact Snapshot
Event Time:
GDRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GDRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GDRX alerts
High impacting GoodRx Holdings, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
GDRX
News
- GoodRx (NASDAQ:GDRX) had its "sell (d)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- GoodRx (NASDAQ:GDRX) was given a new $4.00 price target on by analysts at Morgan Stanley.MarketBeat
- GoodRx to Participate in the 44th Annual J.P. Morgan Healthcare ConferenceBusiness Wire
- Former Steelers QB struggles in his first start with new team [USA TODAY]USA TODAY
- Smart ways to spend your remaining FSA money before year-end deadline [CBS News]CBS News
GDRX
Earnings
- 11/4/25 - Beat
GDRX
Sec Filings
- 12/12/25 - Form 8-K
- 12/8/25 - Form 4
- 12/8/25 - Form 3/A
- GDRX's page on the SEC website